Tags : Jelmyto

UroGen’s Jelmyto Receives the US FDA’s Expedited Approval as a

Shots: The approval is based on P-III OLYMPUS trial results assessing Jelmyto in 74 adults with LG UTUC to evaluate its safety, tolerability and tumor ablative effect across the US and Israel The study resulted in CR 58%, Kaplan-Meier analysis estimated 12-month durability at 84%, median duration of response has not been reached, no treatment-related […]Read More